Daniel J. Lenihan, MD, is one of the Founders and a current Board Member of the International Cardio-Oncology Society. For more than 20 years, he has been committed to improving the cardiovascular care of patients who are receiving treatment for cancer and optimally treating underlying heart disease for those who have survived cancer therapy. He has extensive clinical and research experience in the best treatment and identification of patients at risk for heart failure and other cardiovascular diseases during and after cancer therapy. In combination with Carlo Cipolla, MD in Milan, Italy, and Eric Harrison, MD, in Tampa, Florida, he founded the International Cardio-Oncology Society in 2009. He has personally initiated and fully developed Cardio-Oncology clinical and research programs at several major institutions over the past 20 years. In addition, he has extensive experience in detecting cardiac related toxicity and adverse events during cancer therapy in disciplined clinical research with many presentations and meetings conducted at the major research and regulatory agencies throughout the world. He has a great personal interest and commitment to enhancing education, research and therapeutic options in patients who have amyloidosis. He is an active board member for the non-profit Amyloidosis Foundation.
Daniel J. Lenihan, MD
Daniel J. Lenihan, MD, is one of the Founders and a current Board Member of the International Cardio-Oncology Society. For more than 20 years, he has been committed to improving the cardiovascular care of patients who are receiving treatment for cancer and optimally treating underlying heart disease for those who have survived cancer therapy. He has extensive clinical and research experience in the best treatment and identification of patients at risk for heart failure and other cardiovascular diseases during and after cancer therapy. In combination with Carlo Cipolla, MD in Milan, Italy, and Eric Harrison, MD, in Tampa, Florida, he founded the International Cardio-Oncology Society in 2009. He has personally initiated and fully developed Cardio-Oncology clinical and research programs at several major institutions over the past 20 years. In addition, he has extensive experience in detecting cardiac related toxicity and adverse events during cancer therapy in disciplined clinical research with many presentations and meetings conducted at the major research and regulatory agencies throughout the world. He has a great personal interest and commitment to enhancing education, research and therapeutic options in patients who have amyloidosis. He is an active board member for the non-profit Amyloidosis Foundation.
Daniel Lenihan, MD - Cardio-Oncology specialist
What is Cardio-Oncology and how does it benefit me?
At Cardio-OncologyDoc.com, we offer fast, reliable and innovative solutions for each of these major areas of interest in the world of Cardio-Oncology.
Cardio-Oncology Events
Utilizing Cardiac Biomarkers During Cancer Chemotherapy: How is this Actually Done?
IC-OS Working Group Webinar : Treatment of Cardiac Amyloidosis
November 18, 2021 @ 9:00 - 10:00 am ET
Learn how to diagnose cardiac amyloidosis in a timely fashion, describe current and emerging therapies to manage cardiac amyloidosis, develop an effective treatment strategy to manage cardiac amyloidosis, and explain…..